2篇
您的检索式：作者名="Liteng Lin"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nanodrug enhances post-ablation immunotherapy of hepatocellular carcinoma via promoting dendritic cell maturation and antigen presentation显示文摘Thermal ablation(TA)as an effective method treating hepatocellular carcinoma(HCC)in clinics is facing great challenges of high recurrence and metastasis.Although immune-checkpoint blockade(ICB)-based immuno-therapy has shown potential to inhibit recurrence and metastasis,the combination strategy of ICB and thermal ablation has shown little progress in HCC treatments.The tremendous hurdle for combining ICB with thermal ablation lies with the insufficient antigen internalization and immaturity of tumor-infiltrating dendritic cells(TIDCs)which leads to an inferior immune response to distant tumor growth and metastasis.Herein,an antigen-capturing nanoplatform,whose surface was modified with mannose as a targeting ligand,was constructed for co-delivering tumor-associated antigens(TAAs)and m6A demethylases inhibitor(i.e.,fat mass and obesity asso-ciated gene(FTO)inhibitor)into TIDCs.In vivo results demonstrate that the intratumoral injection of nanodrug followed by HCC thermal ablation promotes dendritic cells(DCs)maturation,improves tumor infiltration of effector T cells and generates immune memory,which synergize with ICB treatment to inhibit the distant tumor growth and lung metastasis.Therefore,the antigen-capturing and FTO-inhibiting nanodrug holds potential to boost the ICB-based immunotherapy against HCC after thermal ablation. | Zecong Xiao Tan Li Xinyao Zheng Liteng Lin Xiaobin Wang Bo Li Jingjun Huang Yong Wang Xintao Shuai Kangshun Zhu | 2023 | Bioactive Materials2023，，3： | 1 |
| 2 | Transarterial chemoembolization combined with sorafenib and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombus:a retrospective controlled study显示文摘To the Editor:Portal vein tumor thrombus(PVTT)is present in 10%to 40%of patients with hepatocellular carcinoma(HCC)at diagnosis and has a profound adverse effect on progno-sis.[1]Sorafenib is recommended as the first-line treatment for patients with advanced HCC,including those who have PVTT.However,its efficacy is modest.[1,2]A combination of transarterial chemoembolization(TACE)and sorafenib(TACE-S)has been reported to be associated with improved outcomes.[1,3]But unfortunately,its efficacy in controlling PVTT remained limited,with an objective response rate(ORR)of only 9.7%.[3]Previous studies have demonstrated that iodine-125(125I)seed brachytherapy targeting PVTT can lead to a significant reduction in tumor thrombus with few complications.[4,5]We hypothesized that TACE-S combined with 125I seed brachytherapy(TACE-S-I)could improve the control of PVTT and confer a greater survival benefit.Therefore,we conducted this study to evaluate the efficacy and safety of TACE-S-I compared with TACE-S in HCC patients with PVTT.This study was approved by our institutional review board(No.2020-hg-ks-03). | Jingjun Huang Mingyue Cai Wensou Huang Yongjian Guo Jingwen Zhou Licong Liang Liteng Lin Zhimei Zhou Hui Lian Mingji He Kangshun Zhu | 2022 | Chinese Medical Journal2022，，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员